Ubiquigent collaborates with University of Glasgow on transl

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

Related Keywords

Mehmet Gundogdu , Niyati Gupta Kheskani , Helen Walden , University Of Glasgow Uo , University Of Glasgow , Ubiquigent Limited , Head Of School Molecular Biosciences , Professor Helen Walden , Principal Scientist , Structural Biology , Molecular Biosciences , Professor Walden , Sheelagh Frame , Chief Scientific Officer , Drug Discovery , Iochemistry , Crystallography , N Vitro , Protein , Research , Research Project , Herapeutics ,